Document is current

Article History

Received: 23 June 2021

Accepted: 19 February 2022

First Online: 22 March 2022

Change Date: 21 July 2022

Change Type: Update

Change Details: The Open Access funding by Projekt DEAL was not included in the original publication, this article has been updated.

Declarations

:

: Informed consent was obtained from the patient included in the study.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: Rachel Wuerstlein reports grants and personal fees from Agendia, Amgen, Aristo, AstraZeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Clinsol, Daiichi-Sankyo, Eisai, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, and Puma Biotechnology outside the submitted work. Nadia Harbeck reports personal fees from Amgen, AstraZeneca, Celgene, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Samsung, and Sandoz outside the submitted work. Sven Mahner reports grants and personal fees from AstraZeneca, Clovis, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Tesaro and Teva outside the submitted work. The other authors declare no conflict of interest.